Connect with us

Artificial Intelligence

Hemato-Oncology Testing Market will value USD 8.56 billion by 2030 : GreyViews



<!– Name:DistributionId Value:8738296 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1257299 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:b90781e2-f73e-495e-8b52-f3b49159983a –>

Pune India, Jan. 28, 2023 (GLOBE NEWSWIRE) — The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the hemato-oncology testing market is operating and is predicted to expand soon. The manufacturers and suppliers involved in the hemato-oncology testing market are present across various countries in the above-mentioned regions.

Get Sample Copy of This Report @

The report provides a detailed understanding of the market segments which have been formed by combining different prospects such as cancer type, product, technology, end-user,  and regions. The key driving factors, restraints, potential growth opportunities and market challenges are also discussed in the paragraphs below.
The significant players operating in the global hemato-oncology testing market are F. Hoffman-La Roche Ltd, Thermo Fisher Scientific, Inc., EntroGen, Inc., Abbott Laboratories, Qiagen N.V., Cepheid, Bio-Rad Laboratories, Inc, Illumina, Inc. among others. To achieve a substantial market share in the worldwide hemato-oncology testing market and strengthen their position, manufacturers are pursuing expansion methods such as current developments, mergers and acquisitions, product innovations, collaborations, and partnerships, joint ventures.
The purpose of hemato oncology testing is to diagnose, treat, and study blood cell, bone marrow, and related tissue cancers. These tests are used to diagnose diseases like sickle cell disease, haemophilia, thalassemia, iron deficiencies, leukemia, and other organ cancers. Sales of assay kits and reagents are driven by the demand for drug discoveries, biotechnology research, and the prevalence of infectious diseases. Assay kits reduce ambiguity by providing accurate diagnostic results, which is boosting sales of market. Another major factor contributing to the growth of the market for hemato oncology testing is the availability of advanced molecular techniques for the diagnosis of hemato oncology. The introduction of advanced molecular techniques has been critical in addressing concerns pertaining to blood cancer prognosis, treatment course, and diagnosis. The government, however, has imposed strict rules and is delaying clearance of experimental molecular diagnostic tests, which may adversely affect market growth during the forecast period. Furthermore, in the near future, artificial intelligence (AI) may become more prevalent in cancer diagnosis, resulting in faster market growth. A number of cancer types are being screened using artificial intelligence. AI-based computer algorithms have helped clinicians interpret mammograms for more than 20 years, and this field is rapidly developing and will create more growth opportunities for the market.

Enquiry Before Buying This Report @

Scope of Hemato-Oncology Testing Market Report:

Report Metric Information
Study Period 2022-2030
Base Year              2022
Forecast Period 2023-2030
Market Share Unit USD Billion
Segments Covered Cancer Type, Product, Technology, End-User, and Regions.
Regions Covered North America, Europe, Asia-Pacific, South America, and Middle-East and Africa
Major Players F. Hoffman-La Roche Ltd, Thermo Fisher Scientific, Inc., EntroGen, Inc., Abbott Laboratories, Qiagen N.V., Cepheid, Bio-Rad Laboratories, Inc, Illumina, Inc. among others

Segmentation Analysis

Lymphoma is expected to be the fastest-growing segment in 2022. 

The cancer type segment includes myeloproliferative neoplasms, leukemia, lymphoma, and others. The lymphoma segment is expected to witness the highest growth rate during the forecast period. A growing awareness of personalized medications and other treatment options is predicted to spur segment growth during the forecast period. As non-Hodgkin and Hodgkin’s lymphomas become more prevalent in the U.S, NHL accounts for 4.2% of all cancer cases. NHL is the seventh most common cancer in the U.S., according to the National Institutes of Health (NIH) in 2019.

Services are expected to be the fastest-growing segment in 2022. 

The product segment is services and assay kits & reagents. The services segment is expected to witness the highest growth rate during the forecast period. As a result of increasing awareness of advanced therapies such as personalized medicine and the rise in leukemia and myeloma cancers, the services segment is expected to dominate the global hemato-oncology test market over the forecast period. The segment is also growing as awareness of advanced treatment therapies such as personalized medicine becomes more prevalent.

Services are expected to be the fastest-growing segment in 2022. 

The technology segment is Cytogenetics, PCR, NGS, IHC, and Others. The PCR segment is expected to witness the highest growth rate during the forecast period. This is due to the fact that it is easy to use, affordable, provides accuracy and efficiency, and is widely accessible. The Diagnostic Laboratories of the BloodCenter of Wisconsin debuted the Abbott RealTime IDH1 assay in July 2018. This PCR test can be performed to find genetic variations in the IDH1 gene from patient bone marrow and blood samples. As a result, it is predicted that an increase in the quantity of PCR-based test launches will promote market expansion at the period of forecasting. In a similar vein, Cepheid’s Xpert BCR-ABL Ultra received FDA approval in October 2019 to monitor a person’s risk of developing chronic myeloid leukaemia. With the use of this in-vitro diagnostic process, complete blood samples taken within three hours might yield precise results.

Services are expected to be the fastest-growing segment in 2022. 

The end-user segment is Academic & Research Institutes, Hospitals, and Others. The hospitals segment is expected to witness the highest growth rate during the forecast period. The availability of specialised laboratory settings, the rise in the incidence rate of blood cancers, the wide range of diagnostic tests available, and the prevalence of healthcare professionals who can conduct diagnostic tests and monitor the disease are all factors contributing to the growth that has been seen.

Regional Analysis           

The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the hemato-oncology testing market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia.

The North American region witnessed a major share. As a major revenue contributor in the region, North America is also a leading contributor globally. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, the aging population, awareness of advanced treatment methods, and strong presence of industry players in the region. During the forecast period, these trends are likely to drive market growth.

Country Analysis

Germany’s hemato-oncology testing market size was valued at USD 0.21 billion in 2022 and is expected to reach USD 0.62 billion by 2030, at a CAGR of 14.6% from 2023 to 2030.
Heavy smoking and binge drinking are most likely to contribute to the rise in cancer rates across the nation. It is significant that strong institutional frameworks, like the German Cancer Consortium and significant University Medical Center-based Comprehensive Cancer Centers, contribute to the advancement of cancer research in all parts of the country (CCCs).

China’s hemato-oncology testing market size was valued at USD 0.22 billion in 2022 and is expected to reach USD 0.66 billion by 2030, at a CAGR of 14.8% from 2023 to 2030.
There is a strong possibility that the rapid growth of medical tourism in the country will lead to a greater demand for cancer treatment and diagnostic procedures. Furthermore, the rise in cancer cases is encouraging hemato-oncology testing, which is boosting the market growth.

India’s hemato-oncology testing market size was valued at USD 0.17 billion in 2022 and is expected to reach USD 0.50 billion by 2030, at a CAGR of 14.7% from 2023 to 2030.
There is a growing prevalence of blood cancer, and a growing number of academic research institutes actively conducting research. This is expected to lead to the highest growth rate in the market.
Covid-19 Impact
Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries.

Furthermore, the growth of this market is mainly driven owing to the rising cases of cancer.

Buy Now Full Report @

Contact Us
Rocky Shah
Pune India
Phone: (+44) 162-237-1047
Email: [email protected]


Follow Us: LinkedIn | Twitter

Browse Related Reports:

Biomedical Sensors Market Size By Type (Wired and Wireless), By Sensor Type (Biochemical Image Sensors, Temperature, Pressure, and Others), By Industry (Pharmaceutical, Healthcare, and Others), Regions, Segmentation, and Projection till 2030

Veterinary Hematology Analyzers Market Size By Product Type (Table Top Analyzers (Fully Automatic Analyzers and Semiautomatic Analyzers) and Point of Care Analyzers (Cartridge-Based Analyzers and Direct Sample Based Analyzers), By Analysis Parameter (2-Part WBC Differential, 3-Part WBC Differential, 5-Part WBC Differential, and Others), By End-User (Research institutes, Veterinary hospitals and clinics, Veterinary diagnostic centers, point-of-care testing, inhouse-testing, and others), Regions, Segmentation, and Projection till 2030

Structural Heart Devices Market Size By Indication (Atrial Septal Defects, Aortic Valvular Disease, Pulmonary Valvular Disease, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Valvular Disease, Patent Ductus Arteriosus, and Others), By Product Type (Heart Valve Devices, Annuloplasty Rings, Occluders and Delivery Systems, Transcatheter Mitral Valve Repair, and Others), By Procedure(Repair and Replacements), Regions, Segmentation, and Projection till 2030  

Shoulder Arthroplasty Market Size By Indication (Arthritis, Fracture/Dislocation, Rotator Cuff Tear Arthropathy, Hill Sachs Defect, and Others), By Device (Shoulder Arthroplasty Resurfacing Implants, Shoulder Arthroplasty Trauma Devices, and Shoulder Arthroplasty Platform Systems), By Procedure (Partial Shoulder Arthroplasty, Total Shoulder Arthroplasty, Reverse Shoulder Arthroplasty, and Revision Shoulder Arthroplasty), Regions, Segmentation, and Projection till 2030

Radiopharmaceuticals Market Size By Procedural Volume (Diagnostic Producers and Therapeutic Procedures), By Application (Endocrinology, Oncology, Neurology, Cardiology, and Others), Regions, Segmentation, and Projection till 2030

Intrathecal Pumps Market Size By Type (Morphine, Baclofen, Ziconotide, Clonidine, Bupivacaine, and Others), By Application (Pain and Spasticity), Regions, Segmentation, and Projection till 2030

Injection Molding Market Size By Material (Metals, Plastics, and Others), By Technology (Electric, Hydraulic, and Hybrid), By Application (Building & Construction, Packaging, Medical, Consumables & Electronics, Automotive & Transportation, and Others), Regions, Segmentation, and Projection till 2030

Influenza Diagnostics Market Size By Test Type (Cell Culture, RIDT, RT-PCR and Others), By End-User (Diagnostic Laboratories, Clinics, Hospitals and Others), Regions, Segmentation, and Projection till 2030  

Intrathecal Pumps Market Size By Type (Morphine, Baclofen, Ziconotide, Clonidine, Bupivacaine, and Others), By Application (Pain and Spasticity), Regions, Segmentation, and Projection till 2030

Embolotherapy Market Size By Disease (Oncology, Peripheral Vascular Diseases and Others), By Embolic Agents (Liquid Embolic Agent, Microspheres, Embolic Coils, Detachable Balloons and Others), By End-User (Ambulatory Surgery Centres, Hospitals & Clinics and Others), Regions, Segmentation, and Projection till 2030  

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

oToBrite Unveils Automotive-Grade 5MP/8MP Camera Modules to Meet Soaring Demand for High-Level ADAS/Autonomous Driving




HSINCHU, Sept. 28, 2023 /PRNewswire/ — oToBrite, a prominent provider of Vision-AI ADAS/AD solutions, has unveiled its latest offering in response to the surging demand for high-level Advanced Driver Assistance Systems (ADAS) and Autonomous Driving (AD) applications. With the need for enhanced perception technology, particularly for heavy commercial vehicles, as the heavier the vehicle is, the longer it will take to stop, oToBrite has successfully introduced automotive-grade 5MP/8MP camera modules. These cutting-edge modules can improve the visibility and perception capabilities of ADAS/AD systems, and have been adopted among clients in North America.

oToBrite has been a leading tier-1 player for vision-AI ADAS/AD solution in the automotive industry, leveraging its full-stack capabilities spanning camera module production technology, edge-computing system design, and vision-AI model development. The company offers flexible business model and comprehensive vision-AI technology stack, enabling it to provide system solutions, camera modules, or AI IP licensing to cater to diverse customer requirements. Its automotive-grade camera modules have already garnered the trust of prominent clients and entered the supply chain of car OEMs such as Luxgen, SONY, Toyota, XPENG, etc. with over 1 million automotive-grade camera modules deployed. To learn more about oToBrite’s offerings, please visit
The newly launched 5MP/8MP camera modules from oToBrite feature high-sensitivity CMOS sensors. oToBrite’s 5MP camera module series is equipped with Sony IMX490 Sensor and has multiple viewing angles, including 30°, 60°, 90°, and 120°. The 8MP camera module series employs Sony IMX728 sensors and also offers various viewing angles. Both 5MP and 8MP series are equipped with GMSL2 interfaces and tested with waterproof and dustproof standards of IP67/69K. They can operate within a temperature range of -40°C to +85°C, ensuring the utmost reliability and stability for customers.
oToBrite holds a distinct advantage in camera production technology, with 1K class clean room factory certified with IATF16949 and endorsed by several leading car OEMs. Additionally, the in-house developed 5/6-axis active alignment machine for high-end camera modules exhibits the capability to manufacture over 60 SKU variants of camera modules.
About oToBrite
oToBrite is a leading vison-AI ADAS/AD solutions provider. Based in Hsinchu Science Park, oToBrite has IATF 16949 certified clean room factory and several years of experience as an automotive Tier-1 supplier. Through comprehensive research and development capabilities, oToBrite provides vision-AI algorithm, ECU/domain controller and automotive-grade/special purpose camera products.
Photo –

View original content:

Continue Reading

Artificial Intelligence

CFOs are the change agents driving shift to servitized business model to harness growth, cost efficiency and technology opportunities




Time for action is now: Customer expectations for servitization already exist (61%) and projected to increase (70%) in the next three years, in terms of value, service and reliability.
LONDON, Sept. 28, 2023 /PRNewswire/ — IFS, the global cloud enterprise software company, has shared the latest findings of its recent global research polling 2,000 senior decision-makers – VP and above – in France, Germany, Japan, Nordics, UK, USA and the UAE –across Manufacturing, Services, Telecoms, Energy & Resources, Construction & Engineering, and A&D industries. In its last overview, the company highlighted the overarching dependence on AI to create and accelerate business value from servitization.  

The survey points to specific executives as drivers or enablers to successfully make the shift and align the organization behind it. The survey highlights the CFO (21%) behind the CEO (35%) as the guardian of business resilience, financial health and as the purse string holder for technology investments. CFOs recognize that the move to servitization is essential in providing predictability in revenues, expenditure and third-party costs, and are aligning themselves to becoming stewards of identifying cross-business strategies that will build competitive advantage. 
At the heart of the business case for servitization, the CFO is focused on three elements: Faster and more cost-efficient time to market, visibility and predictability into revenues and CAPEX, accelerating organization alignment across people, processes and technology, to support not only the processes but also to provide the insights required to assess and optimize as they go within their business and intra-company.  
CFOs exhibit the greatest urgency in implementing a servitized model out of all C-level respondents (CIOs, CHROs and CTOs), with (32%) prioritizing adoption within the next 18 months. This implies change is not only necessary but will deliver business benefits, with progress and success measured by a fully servitized P&L. CFOs are also most likely (26%) to say their role is the one driving the shift within the organization, as they understand how technology capabilities will reach deep into their organization and enable it to become more technology-driven with regards to the design and delivery of products and services: Product R&D (34%) and service R&D (32%) are two areas CFOs prioritized when looking at servitized business processes.  
The priority outcome CFOs want to achieve from servitization is enhancing insight-driven decision-making capabilities (32%) – pointing to why AI is their #1 essential technology choice (49%) as it will fuel faster, more accurate and more data-led inputs into the strategic choices that impact the bottom line.   
Technology as a revenue growth enhancer makes wise fiscal sense. For example, EAM is a must-have for servitization success (34%)– assets that are predictively maintained will last longer, have less downtime and result in less expenditure. FSM (40%) maximizes profitable revenue streams and enables significant cost savings across the service lifecycle through optimized workforce scheduling and planning. Similarly, the wealth of connected asset data that can be harnessed through the application of automation, ML, IoT, end-to-end connectivity – all CFO “must-implements” – explain why CFOs have emerged as such strong proponents of technology and servitization.   
The CFO’s confidence about the organizational readiness is high at (42%) indicating they have the processes mapped out and are progressing well in their move to servitization, but still have either organizational impacts on people and processes (23%) or technology needs to overcome, making the CHRO the second most significant executive to drive and enable the transformation. 
CHROs are more cautious about servitization readiness within the organization, being acutely aware that shifting from a product-focused to a service-focused mindset within their organizations is a barrier to implementing servitization (42%). However, CHROs are in alignment with the CFO on customer expectations for servitization, which are high now, and are set to increase. They also agree that technology is essential to success, with AI their top pick (50%).  
Alex Rumble, SVP of Corporate Communications, Product Marketing, AR, & CI at IFS, commented: “The CFO’s remit has evolved hugely in the last decade away from financial reporting to understanding and influencing business-wide strategies and aiding transformation.” Rumble added, “Our research illustrates this very well and that CFOs not only understand the positive impact of aligning a business behind the customer’s expectations, but also the much broader business value of doing so.” She concluded: “Today CFOs are visionary advocates of change and digital transformation and will help build predictability in revenue and costs, ultimately the holy grail for CFOs but still technology dependent.” 
Together, CFOs and CHROs can partner to be a powerful force to not only accelerate servitization, but also ensure that the whole organization is primed for success. CHROs must act as a secondary catalyst to mobilize cultural change, acting as a bridge between the business and ensuring the communication and implementation of the overall strategy is not siloed to the C-level. 
About IFS 
IFS develops and delivers cloud enterprise software for companies around the world who manufacture and distribute goods, build, and maintain assets, and manage service-focused operations. Within our single platform, our industry specific products are innately connected to a single data model and use embedded digital innovation so that our customers can be their best when it really matters to their customers – at the Moment of Service™. The industry expertise of our people and of our growing ecosystem, together with a commitment to deliver value at every single step, has made IFS a recognized leader and the most recommended supplier in our sector. Our team of over 5,500 employees every day live our values of agility, trustworthiness, and collaboration in how we support our thousands of customers. Learn more about how our enterprise software solutions can help your business today at 
CONTACT: IFS Press Contacts: EUROPE / MEA / APJ: Adam Gillbe IFS, Director of Corporate & Executive Communications Email: [email protected] Phone: +44 7775 114 856
NORTH AMERICA / LATAM: Mairi Morgan IFS, Director of Corporate & Executive Communications Email: [email protected] Phone: +1 520 396 2155
The following files are available for download:–cost-effici,c3220272
CFOs are the change agents driving shift to servitized business model to harness growth, cost efficiency and technology opportunities

View original content:

Continue Reading

Artificial Intelligence

Breaking language barriers: thebigword’s AI workflows enhance translation delivery on time to 99% while significantly reducing turnaround times




LEEDS, England, Sept. 27, 2023 /PRNewswire/ — thebigword, a leading provider of language solutions, is proud to announce an improvement in its on-time delivery performance and significant reduction of turnaround times. This has been made possible through a strategic fusion of human expertise and state-of-the-art AI and Machine Translation technologies.

This exciting achievement reaffirms the company’s commitment to delivering accurate and timely translations to clients worldwide, setting new industry standards.
With the ever-growing demand for rapid and high-quality translations, thebigword has taken numerous steps, including the ability to create and implement self-driving AI workflows, to ensure their clients are receiving the highest quality of translation and customer service.
Through the enhanced integration of AI and Machine Translation solutions into its translation workflows, thebigword has achieved remarkable outcomes, such as the significant reduction in turnaround times and this notable increase in on-time deliveries. With 99% of translation projects across various languages and industries delivered on time to clients, with shorter turnaround times.
thebigword’s collaborative approach leverages the strengths of their human translators with the power of AI technologies to allow for faster translation turnaround times, while maintaining the highest levels of accuracy. Their technology platform also enables quick resource allocation, ensuring that translation projects are assigned, executed and delivered quickly to reduce delivery times.
Joshua Gould, Chief Executive Officer of thebigword Group said: “thebigword is delivering a very human service with the utilisation of next-generation AI. These innovations represent an ongoing effort to enhance the overall client experience through our ability to deliver accurate, high-speed translations at an affordable price for any budget.”
Mark Daley, Global Managing Director of thebigword Translation said: “thebigword understands how crucial timely delivery of accurate translations are for the global success of our clients, and some of the latest technological integrations we have enabled have allowed us to achieve an impressive 99% as well as faster turnaround times.”
As thebigword celebrates this achievement, it looks forward to building on its success with other translation milestones and continuing to provide high-quality translation services – further enabling its mission of eradicating the final barrier of global communication.
About thebigword:
As one of the largest language service providers globally, thebigword utilises the greatest minds and boundary-shattering technology to deliver phenomenal quality at scale to both our clients and linguist network.
thebigword provides the best translation, interpretation, localisation and language technology solutions for businesses, the public sector and individuals – handling up to 50,000 worldwide assignments every day.
For more information about thebigword’s innovative AI and Machine Translation solutions, please visit
Logo –
For media enquiries, please contact:Lauren HockneyGlobal Head of [email protected]

View original content:

Continue Reading

Latest News